质量改进实施新生儿单纯疱疹病毒标准化诊疗
在1家独立儿童医院开展质量改进项目,通过提高指南可及性和医护人员参与度,将0至60天患儿按本地指南推荐进行HSV检测和治疗的百分比从40%提升至80%。非高危患儿阿昔洛韦使用率从26%降至7.9%(P < .001),高危患儿使用率无显著变化(73%-83%,P = .15),HSV阳性病例中无延迟启动阿昔洛韦治疗。
要点
- 通过质量改进方法可将新生儿HSV指南依从性从40%提升至80%。
- 非高危患儿阿昔洛韦使用率从26%降至7.9%(P < .001)。
- 高危患儿阿昔洛韦使用率无显著变化(73%-83%,P = .15)。
核心结论
- 基于证据的指南床旁可及性和针对医护人员参与度的干预措施,提高了新生儿HSV管理新指南的依从性,并减少了非高危婴儿的阿昔洛韦使用。
研究设计与样本
- 在1家独立儿童医院开展的质量改进项目,采用多个计划-执行-研究-行动(PDSA)循环,针对关键驱动因素包括医护人员认可、指南可及性和高危患者准确识别进行干预。
主要发现
- 按指南推荐管理的患者中位数百分比在8个月内从40%升至80%。
- 非高危患者阿昔洛韦使用率从26%降至7.9%(P < .001)。
- 高危患者阿昔洛韦使用率从73%至83%,无显著变化(P = .15)。
- HSV阳性病例中无延迟启动阿昔洛韦治疗(定义为就诊后超过1天启动)。
关键数值与推荐
- 目标是将0至60天年龄患儿按本地指南推荐进行HSV检测和治疗的百分比从40%提高至80%。
临床怎么用
- 在儿科临床中,可通过确保循证指南床旁可及和促进医护人员参与来实施新生儿HSV标准化管理,从而在非高危婴儿中减少不必要的阿昔洛韦使用。
局限性
- 需进一步研究以在其他机构中确认这些推荐的安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Neonatal herpes simplex virus (HSV) infections are associated with high mortality and long-term morbidity. However, incidence is low and acyclovir, the treatment of choice, carries risk of toxicity. We aimed to increase the percentage of patients 0 to 60 days of age who are tested and treated for HSV in accordance with local guideline recommendations from 40% to 80%. METHODS: This quality improvement project took place at 1 freestanding children's hospital. Multiple plan-do-study-act cycles were focused on interventions aimed at key drivers including provider buy-in, guideline availability, and accurate identification of high-risk patients. A run chart was used to track the effect of interventions on the percentage managed per guideline recommendations over time by using established rules for determining special cause. Pre- and postimplementation acyclovir use was compared by using a χ2 test. In HSV-positive cases, delayed acyclovir initiation, defined as >1 day from presentation, was tracked as a balancing measure. RESULTS: The median percentage of patients managed according to guideline recommendations increased from 40% to 80% within 8 months. Acyclovir use decreased from 26% to 7.9% (P < .001) in non-high-risk patients but did not change significantly in high-risk patients (73%-83%; P = .15). There were no cases of delayed acyclovir initiation in HSV-positive cases. CONCLUSIONS: Point-of-care availability of an evidence-based guideline and interventions targeted at provider engagement improved adherence to a new guideline for neonatal HSV management and decreased acyclovir use in non-high-risk infants. Further study is necessary to confirm the safety of these recommendations in other settings.
引用
- Brower LH, Wilson PM, Murtagh Kurowski E, et al. Using Quality Improvement to Implement a Standardized Approach to Neonatal Herpes Simplex Virus. Pediatrics. 2019. PMID: 31345997. doi:10.1542/peds.2018-0262
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。